Trial Completed: Clinical Trial Using Humira in Netherton Syndrome (NCT02113904)
WHY IT MATTERS
This completed trial provides evidence about whether Humira—a drug already used for other inflammatory conditions—could be repurposed to treat Netherton syndrome, which currently has very limited treatment options.
Researchers completed a small study testing whether a drug called Adalimumab (brand name Humira) could help people with Netherton syndrome, a rare skin condition that causes severe itching, rashes, and inflammation. Eleven patients received the drug for 3 months and were then followed for another 3 months to see if it was safe and if it improved their symptoms, including pain and itching.
NCT ID: NCT02113904 Status: COMPLETED Conditions: Netherton Syndrome Phase: PHASE2 Enrollment: 11 Sponsor: Assistance Publique - Hôpitaux de Paris Summary: The main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome after 3 months of treatment , with a post treatment period follow-up of 3 months. Second objectives are To evaluate the safety of Adalimumab in the context of NS To evaluate the improvement of the quality of life at 3 months To evaluate the improvement of pruritus and pain in the patients To study markers of inflammatory and